# Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly

> **NCT05398926** · PHASE4 · COMPLETED · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 400 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine (Vero cell), Inactivated

## Key facts

- **NCT ID:** NCT05398926
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398926, "Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05398926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*